Children's Antimicrobial Management Program (ChAMP)

MONOGRAPH

Nystatin Monograph - Paediatric

Scope (Staff):	Medical, Pharmacy, Nursing
Scope (Area):	All Clinical Areas

Child Safe Organisation Statement of Commitment

CAHS commits to being a child safe organisation by applying the National Principles for Child Safe Organisations. This is a commitment to a strong culture supported by robust policies and procedures to reduce the likelihood of harm to children and young people.

This document should be read in conjunction with this **DISCLAIMER**

QUICKLINKS				
Dosage/Dosage Adjustments	<u>Administration</u>	<u>Monitoring</u>		

DRUG CLASS

Polyene antifungal.(1)

INDICATIONS AND RESTRICTIONS

Nystatin is indicated for treatment and prophylaxis for oropharyngeal candidiasis. (1)

Oral: Unrestricted (green) antifungal

This is not a restricted agent. Follow standard ChAMP guidelines where appropriate.

CONTRAINDICATIONS

Hypersensitivity to nystatin or any component of the formulation. (2-5)

PRECAUTIONS

- Oral nystatin should NOT be used in the treatment of systemic fungal infections as it is not absorbed from the gastrointestinal tract.^(2, 4)
- Topical nystatin is generally not used in the treatment of severe oropharyngeal candidiasis or in immunosuppressed patients. An alternative agent should be considered.^(1, 6)

FORMULATIONS

Listed below are products available at PCH. Other formulations may be available, check with pharmacy if required:

100,000 units/mL oral liquid

Imprest location: Formulary One

DOSAGE & DOSAGE ADJUSTMENTS

Neonates: Refer to Neonatal Medication Protocols and ChAMP Antifungal Prophylaxis
Guideline

Oral liquid:

Prophylaxis of Oropharyngeal candidiasis:

≥4 weeks to 18 years of age: 100,000 units (1 mL) four times a day.⁽³⁾

Treatment of Oropharyngeal candidiasis:

- ≥4 weeks to 18 years of age: 100,000 units (1 mL) four times a day. Dose can be increased up to 500,000 units four times a day if severe. (1, 6)
- Treatment should continue for 7 to 14 days OR 48 hours after clinical resolution. (2, 3, 7)

Renal impairment:

No dosage adjustments required in renal impairment. (3, 5)

Hepatic impairment:

No dosage adjustments required in hepatic impairment. (3, 5)

ADMINISTRATION

Oral suspension

- The oral suspension should be shaken well before measuring the required dose and is best given after food or feeds. (1-3, 7)
- The suspension should be swished around the mouth for as long as comfortable before being swallowed. For younger patients in whom this is not possible, the suspension can be dropped or painted onto the affected areas.^(2, 5)
- Administer half the dose on each side of the mouth and avoid food for 5 to 10 minutes after the dose.⁽³⁾

MONITORING

Monitor for resolution of symptoms and if appropriate take fungal cultures.

ADVERSE EFFECTS

Common: nausea, vomiting, diarrhoea (more common with higher doses), dyspepsia. (1, 3)

Rare: Skin reactions, Stevens-Johnson syndrome, hypersensitivity, facial oedema, angioedema. (8)

STORAGE

Nystatin should be stored below 25°C.(2)

INTERACTIONS

This medication may interact with other medications; consult PCH approved references (e.g. Clinical Pharmacology), a clinical pharmacist or PCH Medicines Information Service on extension 63546 for more information.

Related CAHS internal policies, procedures and guidelines

Antimicrobial Stewardship Policy

ChAMP Empiric Guidelines and Monographs

KEMH Neonatal Medication Protocols

References

- 1. Australian Medicines Handbook. Adelaide, S. Aust.: Australian Medicines Handbook; 2025 [cited 2025 6th March]. Available from: https://amhonline-amh-net-au.pklibresources.health.wa.gov.au/.
- 2. AusDI [Internet]. Health Communication Network Pty Ltd. 2025 [cited 2025 March 6th].
- 3. Clinical Pharmacology powered by ClinicalKey [Internet]. Elsvier. 2025 [cited 2025 March 6th]. Available from: https://www-clinicalkey-com.pklibresources.health.wa.gov.au/pharmacology/.
- 4. Electronic Medicines Compendium (emc). Surrey: DataPharm Ltd; 2024.
- 5. Up To Date Paediatric Drug information [Internet]. Lexicomp. 2025 [cited 2025 March 6th]. Available from: https://www-uptodate-com.pklibresources.health.wa.gov.au/contents/table-of-contents/drug-information/pediatric-drug-information.
- 6. Royal Australian College of General Practitioners, Pharmaceutical Society of Australia, Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists. AMH: Children's Dosing Companion. Adelaide: Australian Medicines Handbook Pty Ltd; 2022.
- 7. Antibiotic Writing Group. Therapeutic Guidelines Antibiotic. West Melbourne: Therapeutic Guidelines Ltd; 2022. Available from: https://tgldcdp-tg-org-au.pklibresources.health.wa.gov.au/etgAccess.
- 8. Paediatric Formulary Committee. BNF for Children: 2025. London: BMJ Group Pharmaceutical Press; 2025.

^{**}Please note: The information contained in this guideline is to assist with the preparation and administration of **nystatin**. Any variations to the doses recommended should be clarified with the prescriber prior to administration**

This document can be made available in alternative formats on request.

File Path:	W:\Safety & Quality\CAHS\CLOVERS MEDICAL Pharmacy\Procedures Protocols and Guidelines\ChAMP\Word			
Document Owner:	Head of Department – Infectious Diseases			
Reviewer / Team:	Children's Antimicrobial Management Program Pharmacist			
Date First Issued:	November 2015	Last Reviewed:	March 2025	
Amendment Dates:	March 2019, February 2022	Next Review Date:	March 2028	
Approved by:	CAHS Drug and Therapeutics Committee	Date:	April 2025	
Endorsed by:	Chair, CAHS Drugs and Therapeutics Committee	Date:	April 2025	
Aboriginal Impact Statement and Declaration (ISD)		Date ISD approved:	August 2023	
Standards Applicable:	NSQHS Standards: POOL OF THE STANDARD S			

Printed or personally saved electronic copies of this document are considered uncontrolled



Respect

Neonatology | Community Health | Mental Health | Perth Children's Hospital